日本糖尿病藥物市場報告（按類型（胰島素、口服降血糖藥、非胰島素注射劑、複方製劑）、配銷通路（線上藥局、醫院藥局、零售藥局）及地區分類，2026-2034年）

Japan Diabetes Drugs Market Report by Type (Insulins, Oral Anti-diabetic Drugs, Non-Insulin Injectable Drugs, Combination Drugs), Distribution Channel (Online Pharmacies, Hospital Pharmacies Retail Pharmacies), and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 117 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本糖尿病藥物市場規模達46億美元。展望未來， IMARC Group預計到2034年，該市場規模將達到61億美元，2026年至2034年間的複合年成長率（CAGR）為3.33%。推動市場成長的主要因素是，越來越多成熟的製藥公司致力於研發、生產和銷售各種糖尿病藥物，旨在有效控制血糖水平。

本報告解答的關鍵問題：

日本糖尿病藥物市場目前表現如何？未來幾年又將如何發展？
新冠疫情對日本糖尿病藥物市場產生了哪些影響？
日本糖尿病藥物市場按類型分類的組成是怎樣的？
日本糖尿病藥物市場按配銷通路分類的組成是怎樣的？
日本糖尿病藥物市場價值鏈的各個階段有哪些？
日本糖尿病藥物的關鍵促進因素和挑戰是什麼？
日本糖尿病藥物市場的結構是怎麼樣的？主要參與者有哪些？
日本糖尿病藥物市場的競爭程度如何？

Japan diabetes drugs market size reached USD 4.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 6.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.33% during 2026-2034. The rising number of established pharmaceutical companies engaged in the development, production, and distribution of a diverse range of diabetes medications, each aiming to control blood glucose levels effectively is primarily driving the market growth

Diabetes drugs play a pivotal role in managing and treating diabetes, a chronic condition characterized by elevated blood sugar levels due to the body's inability to produce sufficient insulin or utilize it effectively. These pharmaceutical agents are crucial in controlling the progression of the disease and mitigating the risk of complications, such as cardiovascular disease, kidney damage, and vision loss. There are various classes of diabetes drugs, each working differently to regulate blood glucose levels. Some are designed to boost insulin secretion, while others improve insulin sensitivity or decrease the amount of glucose absorbed by the intestines.

Japan Diabetes Drugs Market Trends:

The Japan diabetes drugs market is a rapidly evolving sector, responding to the escalating need stemming from the widespread prevalence of diabetes in the region, predominantly influenced by aging demographics and lifestyle alterations. The dynamics of this market are shaped by the infusion of innovative solutions and relentless research endeavors by prominent pharmaceutical entities, aimed at devising diverse medication strategies to meticulously regulate blood glucose levels. The market is experiencing substantial growth, fueled by a heightened awareness and understanding of diabetes and its associated complications. The propensity towards embracing novel and effective diabetes medications is prominent in Japan, with a significant inclination towards the integration of advanced drugs, such as GLP-1 receptor agonists, which are gaining traction due to their efficacy and multifunctionality in managing blood sugar levels and weight. A distinctive trend in the market is the burgeoning investment in R&D activities, fostering the development of groundbreaking drugs with enhanced capabilities and reduced side effects. The advent of personalized medicine is also playing a pivotal role in shaping the market landscape, enabling more tailored and patient-centric approaches to treatment. The heightened emphasis on healthcare and wellness, coupled with supportive regulatory frameworks and substantial healthcare expenditure, is anticipated to propel the regional market forward over the forecasted period.

Japan Diabetes Drugs Market Segmentation:

Type Insights:

Insulins
- Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
- Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
- Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
- Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic Drugs
- Biguanides
Metformin
- Alpha-Glucosidase Inhibitors
- Dopamine D2 Receptor Agonist
Bromocriptin
- SGLT-2 Inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
- DPP-4 Inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
- Sulfonylureas
- Meglitinides
Non-Insulin Injectable Drugs
- GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
- Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
- Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
- Oral Combination
Janumet (Sitagliptin and Metformin)

Distribution Channel Insights:

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan diabetes drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan diabetes drugs market?
What is the breakup of the Japan diabetes drugs market on the basis of type?
What is the breakup of the Japan diabetes drugs market on the basis of distribution channel?
What are the various stages in the value chain of the Japan diabetes drugs market?
What are the key driving factors and challenges in the Japan diabetes drugs?
What is the structure of the Japan diabetes drugs market and who are the key players?
What is the degree of competition in the Japan diabetes drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Diabetes Drugs Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Diabetes Drugs Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Diabetes Drugs Market - Breakup by Type

6.1 Insulins
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Segmentation
  - 6.1.3.1 Basal or Long Acting Insulins
    - 6.1.3.1.1 Lantus (Insulin Glargine)
    - 6.1.3.1.2 Levemir (Insulin Detemir)
    - 6.1.3.1.3 Toujeo (Insulin Glargine)
    - 6.1.3.1.4 Tresiba (Insulin Degludec)
    - 6.1.3.1.5 Basaglar (Insulin Glargine)
  - 6.1.3.2 Bolus or Fast Acting Insulins
    - 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
    - 6.1.3.2.2 Humalog (Insulin Lispro)
    - 6.1.3.2.3 Apidra (Insulin Glulisine)
  - 6.1.3.3 Traditional Human Insulins
    - 6.1.3.3.1 Novolin/Actrapid/Insulatard
    - 6.1.3.3.2 Humulin
    - 6.1.3.3.3 Insuman
  - 6.1.3.4 Biosimilar Insulins
    - 6.1.3.4.1 Insulin Glargine Biosimilars
    - 6.1.3.4.2 Human Insulin Biosimilars
- 6.1.4 Market Forecast (2026-2034)
6.2 Oral Anti-diabetic Drugs
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Segmentation
  - 6.2.3.1 Biguanides
    - 6.2.3.1.1 Metformin
  - 6.2.3.2 Alpha-Glucosidase Inhibitors
  - 6.2.3.3 Dopamine D2 Receptor Agonist
    - 6.2.3.3.1 Bromocriptin
  - 6.2.3.4 SGLT-2 Inhibitors
    - 6.2.3.4.1 Invokana (Canagliflozin)
    - 6.2.3.4.2 Jardiance (Empagliflozin)
    - 6.2.3.4.3 Farxiga/Forxiga (Dapagliflozin)
    - 6.2.3.4.4 Suglat (Ipragliflozin)
  - 6.2.3.5 DPP-4 Inhibitors
    - 6.2.3.5.1 Onglyza (Saxagliptin)
    - 6.2.3.5.2 Tradjenta (Linagliptin)
    - 6.2.3.5.3 Vipidia/Nesina (Alogliptin)
    - 6.2.3.5.4 Galvus (Vildagliptin)
  - 6.2.3.6 Sulfonylureas
  - 6.2.3.7 Meglitinides
- 6.2.4 Market Forecast (2026-2034)
6.3 Non-Insulin Injectable Drugs
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Segmentation
  - 6.3.3.1 GLP-1 Receptor Agonists
    - 6.3.3.1.1 Victoza (Liraglutide)
    - 6.3.3.1.2 Byetta (Exenatide)
    - 6.3.3.1.3 Bydureon (Exenatide)
    - 6.3.3.1.4 Trulicity (Dulaglutide)
    - 6.3.3.1.5 Lyxumia (Lixisenatide)
  - 6.3.3.2 Amylin Analogue
    - 6.3.3.2.1 Symlin (Pramlintide)
- 6.3.4 Market Forecast (2026-2034)
6.4 Combination Drugs
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.1.2 Market Segmentation
  - 6.3.3.1 Insulin Combinations
    - 6.3.3.1.1 NovoMix (Biphasic Insulin Aspart)
    - 6.3.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    - 6.3.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
  - 6.3.3.2 Oral Combinations
    - 6.3.3.2.1 Janumet (Sitagliptin and Metformin)
- 6.4.4 Market Forecast (2026-2034)

7 Japan Diabetes Drugs Market - Breakup by Distribution Channel

7.1 Online Pharmacies
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Hospital Pharmacies
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Retail Pharmacies
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)

8 Japan Diabetes Drugs Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Type
- 8.1.4 Market Breakup by Distribution Channel
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Type
- 8.2.4 Market Breakup by Distribution Channel
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Type
- 8.3.4 Market Breakup by Distribution Channel
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Type
- 8.4.4 Market Breakup by Distribution Channel
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Type
- 8.5.4 Market Breakup by Distribution Channel
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Type
- 8.6.4 Market Breakup by Distribution Channel
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Type
- 8.7.4 Market Breakup by Distribution Channel
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Type
- 8.8.4 Market Breakup by Distribution Channel
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Diabetes Drugs Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Diabetes Drugs Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis